pomalidomide has been researched along with Local Neoplasm Recurrence in 82 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.22) | 29.6817 |
| 2010's | 38 (46.34) | 24.3611 |
| 2020's | 43 (52.44) | 2.80 |
| Authors | Studies |
|---|---|
| Bringhen, S; Campana, F; Dimopoulos, MA; Harrison, SJ; Le-Guennec, S; Macé, S; Richardson, PG; Schjesvold, F; Yong, K | 1 |
| Antonioli, E; Attucci, I; Bocchia, M; Buda, G; Candi, V; Ciofini, S; Del Giudice, ML; Fontanelli, G; Formica, G; Galimberti, S; Ghio, F; Gozzetti, A; Orciuolo, E; Petrini, M | 1 |
| Berenson, JR; Eades, B; Eshaghian, S; Ghermezi, M; Lim, S; Martinez, D; Schwartz, G; Spektor, TM; Swift, RA; Vescio, R; Yashar, D | 1 |
| Ide, T; Osawa, M; Sanghavi, K; Vezina, HE | 1 |
| Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K | 1 |
| Anderson, L; Basu, S; Djebbari, F; Eyre, TA; Maddams, R; Poynton, M; Ramasamy, K; Sangha, G; Vallance, G | 1 |
| Aslam, M; Gul, E; Jimenez-Zepeda, VH; Kardjadj, M; Kotb, R; LeBlanc, R; Louzada, M; Masih-Khan, E; McCurdy, A; Mian, H; Reece, D; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Brillac, C; Fau, JB; Gaudel-Dedieu, N; Koiwai, K; Nguyen, L; Rachedi, F; Sebastien, B; Semiond, D; Thai, HT; van de Velde, H; Veyrat-Follet, C | 1 |
| Chung, W; Iida, S; Iwasaki, H; Kuroda, J; Kuwayama, S; Lee, K; Matsue, K; Matsumoto, M; Nishio, M; Sugiura, I; Sunami, K | 1 |
| Campana, F; Huang, SY; Iida, S; Ikeda, T; Iyama, S; Kaneko, H; Kim, JS; Kim, K; Koh, Y; Lee, JH; Lin, TL; Matsumoto, M; Min, CK; Shimazaki, C; Sunami, K; Suzuki, K; Tada, K; Uchiyama, M; Wang, MC; Yeh, SP | 1 |
| Anderson, L; Basker, N; Basu, S; Bygrave, C; Chauhan, SR; Djebbari, F; Eyre, TA; Firas, AK; Gudger, A; Karim, F; Lam, HPJ; Maddams, R; Morgan, L; Ngu, L; Obeidalla, A; Panitsas, F; Poynton, M; Prideaux, S; Ramasamy, K; Rampotas, A; Salhan, B; Sangha, G; Soutar, R; Triantafillou, M; Tsagkaraki, I; Vallance, G; Walker, M; Yang, L; Young, J | 1 |
| Bathija, S; Berringer, H; Dwarakanathan, HR; He, J; Heeg, B; Johnston, S; Kampfenkel, T; Lam, A; Mackay, E; Mendes, J; Ruan, H | 1 |
| Aebi, S; Driessen, C; Goede, J; Hayoz, S; Lerch, E; Maniecka, Z; Mey, U; Novak, U; Pabst, T; Renner, C; Rhyner Agocs, G; Rüfer, A; Schär, S; Zander, T | 1 |
| Al-Kaisi, F; Anderson, L; Basker, N; Basu, S; Bygrave, C; Chauhan, SR; Djebbari, F; Eyre, TA; Gudger, A; Karim, F; Kothari, J; Lam, HPJ; Maddams, R; Morgan, L; Ngu, L; Obeidalla, A; Panitsas, F; Poynton, M; Prideaux, S; Ramasamy, K; Rampotas, A; Salhan, B; Sangha, G; Soutar, R; Triantafillou, M; Tsagkaraki, I; Vallance, G; Walker, M; Yang, L; Young, J | 1 |
| Brander, DM; Ding, W; Gui, M; He, W; Huntington, SF; Iqbal, M; Kearney, AS; Koehler, AB; Leis, JF; Mato, AR; McKinlay, TP; Moustafa, MA; Rosenthal, AC; Schuster, SJ; Tun, HW | 1 |
| Du, J; Fu, WJ; Guo, P; He, HY; Jiang, H; Li, L; Liu, J; Lu, J; Qiang, WT | 1 |
| Fu, CC; Jin, S; Ma, X; Shang, JJ; Wang, J; Wu, DP; Yao, Y | 1 |
| Boyle, J; Bright, S; Capra, M; Chraniuk, D; Currie, B; Delimpasi, S; Dimopoulos, MA; He, W; Hungria, VTM; Leleu, X; Li, J; Li, M; Low, M; Maiolino, A; Masszi, T; Matsumoto, M; McKeown, A; Mikala, G; Opalinska, J; Osipov, I; Pappa, V; Perera, S; Radinoff, A; Roy-Ghanta, S; Sule, N; Weisel, K | 1 |
| Asaoku, H; Chim, CS; Chng, WJ; Durie, B; Gopalakrishnan, SK; Huang, SY; Kim, JS; Kim, K; Kimura, H; Kosugi, H; Lee, JH; Lee, JJ; Lee, SL; Min, CK; Moorakonda, R; Nagarajan, C; Sakamoto, J; Soekojo, CY; Takezako, N; Wei, Y; Yoon, SS | 1 |
| Anderson, KC; Attal, M; Beksac, M; Campana, F; Cavo, M; Corzo, KP; Dimopoulos, MA; Dubin, F; Huang, JS; Le-Guennec, S; Leleu, X; Macé, S; Minarik, J; Moreau, P; Prince, HM; Rajkumar, SV; Richardson, PG; San-Miguel, J; Schjesvold, F; Spicka, I | 1 |
| Kassir, N; Li, Y; Palmisano, M; Wang, X; Zhou, S | 1 |
| Agis, H; Blank, A; Blau, IW; Chatterjee, M; Einsele, H; Engelhardt, M; Ferstl, B; Goldschmidt, H; Griese, J; Härtle, S; Jarutat, T; Peschel, C; Raab, MS; Röllig, C; Schub, N; Weirather, J; Weisel, K; Winderlich, M | 1 |
| Anttila, P; Basu, S; Ben-Yehuda, D; Biyukov, T; Byeff, P; Cascavilla, N; Dhanasiri, S; Dimopoulos, M; Grote, L; Guo, S; Hayden, PJ; Hus, M; Johnson, P; Kanate, AS; Krauth, MT; Larocca, A; Lucio, P; Mendeleeva, L; Moreau, P; Muelduer, E; Richardson, P; Rodríguez-Otero, P; Vural, F; Weisel, K; Yagci, M; Yu, X | 1 |
| Biyukov, T; Matsue, K; Peluso, T; Richardson, P; Sakurai, S; Shinagawa, A; Sunami, K; Suzuki, K; Takezako, N; Tamakoshi, H | 1 |
| Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Matous, J; Pierceall, WE; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K; Talamo, G; Zafar, F | 1 |
| Ichinohe, T; Ishibashi, H; Kikumto, M; Maruyama, H; Nakamichi, K; Saijo, M; Takahashi, T; Takebayashi, Y; Ueno, H; Umemoto, K; Yasutomi, H | 1 |
| Assadourian, S; Campana, F; Dimopoulos, MA; Harrison, SJ; Leleu, X; Liberati, AM; Malinge, L; Miles Prince, H; Moreau, P; Ocio, EM; Richardson, PG; Sémiond, D; van de Velde, H; Yong, K | 1 |
| Bladé, J; Cejalvo, MJ; de Arriba, F; de la Rubia, J; Dourdil, MV; García-Malo, MD; García-Mateo, A; García-Sanz, R; Lahuerta, JJ; Martín-Sánchez, J; Martínez-López, J; Mateos, MV; Motlló, C; Ocio, EM; Oriol, A; Rodríguez-Otero, P; San-Miguel, JF | 1 |
| Alegre, A; Bensfia, S; Bringhen, S; Campana, F; Facon, T; Frenzel, L; Guillonneau, S; Jurczyszyn, A; Le-Guennec, S; Lin, PL; Min, CK; Richardson, PG; Schjesvold, FH; Spencer, A; Sunami, K; van de Velde, H | 1 |
| Einsele, H; Grathwohl, D; Kortüm, KM; Krummenast, F; Leicht, HB; Meckel, K; Nickel, K; Rasche, L; Steinhardt, MJ; Zhou, X | 1 |
| Richardson, PG | 1 |
| Anderson, LD; Biyukov, T; Casal, E; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Jenner, M; Moreau, P; Nguyen, TV; Pavic, M; Peluso, T; Richardson, P; Salomo, M; San-Miguel, J; Sonneveld, P; Srinivasan, S; Weisel, K; White, D; Yu, X | 1 |
| Agarwal, A; Amatangelo, MD; Bahlis, NJ; Chung, W; Neri, P; Parekh, S; Pierceall, WE; Rahman, A; Serbina, N; Siegel, DS; Thakurta, A; Van Oekelen, O; Young, M | 1 |
| Brillac, C; Campana, F; El-Cheikh, R; Fau, JB; Koiwai, K; Mace, N; Nguyen, L; Semiond, D | 1 |
| Abdallah, AO; Atrash, S; Ganguly, S; Kawsar, H; Mahmoudjafari, Z; McGuirk, J; Mohyuddin, GR; Shune, L; Sigle, M | 1 |
| van de Donk, NWCJ | 1 |
| Benettaib, B; Kassir, N; Li, Y; Ogasawara, K; Palmisano, M; Wang, X; Zhou, S | 1 |
| Barchnicka, A; Bednarczyk, M; Grosicka, O; Grosicki, S | 1 |
| Chari, A; Delea, TE; Hagiwara, M; Kee, A; Madduri, D; Parikh, K; Pelletier, C | 1 |
| Branagan, AR; Dhodapkar, KM; Dhodapkar, MV; Flavell, RA; Verma, R; Xu, ML | 1 |
| Anupindi, VR; Kudaravalli, S; Richter, J; Shah, D; Yeaw, J; Zavisic, S | 1 |
| Bensinger, WI; Campana, F; Chiron, M; Facon, T; Leleu, X; Macé, S; Mikhael, J; Richardson, PG; van de Velde, H | 1 |
| Piggin, A; Prince, HM | 1 |
| Bensinger, WI; Bianchi, G; Campana, F; D'Souza, A; Dubin, F; Kanagavel, D; Karanes, C; Laubach, JP; Raje, N; Richardson, PG; Saleem, R; Sborov, D; Tuchman, SA; Usmani, SZ | 1 |
| Ahmadi, T; Amin, H; Baldini, L; Beksac, M; Bila, J; Boccadoro, M; Carson, R; Delimpasi, S; Dimopoulos, MA; Einsele, H; Kampfenkel, T; Katodritou, E; Mateos, MV; Moreau, P; Orfanidis, I; Oriol, A; Qiu, Y; Schecter, JM; Sonneveld, P; Symeonidis, A; Terpos, E; Ukropec, J; Vermeulen, J | 1 |
| A Dimopoulos, M; Bringhen, S; Facon, T; Foster, MC; G Richardson, P; Hulin, C; Leleu, X; Moreau, P; Perrot, A; Poole, EM; Schjesvold, F; Tekle, C; van de Velde, H | 1 |
| Goldschmidt, H; Kellermann, L; Knauf, W; Kohnke, J; Merz, M; Poenisch, W; Tischler, HJ | 1 |
| Anttila, P; Bahlis, N; Biyukov, T; Cavo, M; Chen, C; Cook, G; Corradini, P; Delforge, M; Dimopoulos, MA; Hansson, M; Herring, J; Hong, K; Joao, C; Kaiser, M; Moreau, P; O'Gorman, P; Oriol, A; Raymakers, R; Richardson, PG; San-Miguel, J; Siegel, DS; Slaughter, A; Song, K; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Ahmadi, T; Arnulf, B; Chari, A; Chiu, C; Comenzo, R; Fay, JW; Ifthikharuddin, JJ; Kaufman, JL; Khokhar, NZ; Krishnan, A; Lentzsch, S; Lonial, S; Nottage, K; Suvannasankha, A; Wang, J; Weiss, BM | 1 |
| Anderson, KC; Attal, M; Campana, F; Corzo, K; Hui, AM; Le-Guennec, S; Richardson, PG; Risse, ML | 1 |
| Atherton, PJ; DeAngelis, LM; Grommes, C; Jaeckle, KA; Johnston, PB; Koenig, PA; O'Neill, B; Omuro, AMP; Pederson, LD; Pulido, J; Reeder, CB; Schiff, D; Tun, HW; Witzig, TE | 1 |
| Nougawa, M; Oka, S; Shimazu, Y; Shiragami, H; Takeuchi, S | 1 |
| Abella, E; Bladé, J; Cabezudo, E; Cibeira, MT; Clapés, V; Escoda, L; Fernández de Larrea, C; García-Guiñón, A; Gironella, M; Granell, M; Isola, I; Jiménez-Segura, R; López-Pardo, J; Oriol, A; Rosiñol, L; Soler, JA; Tovar, N | 1 |
| Boyer, A; Coleman, M; Forsberg, PA; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, KA; Perry, A; Rossi, AC; Tegnestam, L | 1 |
| Anderson, K; Bensinger, W; Campana, F; Dubin, F; Kanagavel, D; Karanes, C; Liu, Q; Mikhael, J; Raje, N; Richardson, P; Semiond, D; Usmani, SZ | 1 |
| Boise, LH; Gleason, C; Gupta, VA; Heffner, LT; Joseph, NS; Kaufman, JL; Lonial, S; Nooka, AK | 1 |
| Capalbo, SF; Cascavilla, N; Curci, P; Di Renzo, N; Falcone, AP; Fragasso, A; Guarini, A; Mazza, P; Mele, A; Mele, G; Miccolis, MR; Musto, P; Palazzo, G; Palumbo, G; Pastore, D; Pavone, V; Quinto, AM; Reddiconto, G; Rizzi, R; Specchia, G; Tarantini, G | 1 |
| Berdeja, JG; Berenson, JR; Chang, YL; Klippel, Z; Lyons, RM; Niesvizky, R; Rifkin, RM; Shah, J; Stadtmauer, EA; Usmani, S | 1 |
| Forsberg, PA; Mark, TM | 1 |
| Alegre, A; Banos, A; Belch, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, M; Garderet, L; Goldschmidt, H; Ivanova, V; Jacques, C; Karlin, L; Lacy, M; Martinez-Lopez, J; Miguel, JS; Moreau, P; Oriol, A; Palumbo, A; Schey, S; Song, K; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH | 1 |
| Gentili, S; Lonial, S | 1 |
| Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L | 1 |
| Bátorová, A; Mistrík, M; Roziaková, L | 1 |
| Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG | 1 |
| Amatya, R; Belch, A; Dimopoulos, MA; Jacques, C; Monzini, MS; Moreau, P; Palumbo, A; San Miguel, J; Schey, S; Song, KW; Sonneveld, P; Sternas, L; Weisel, KC; Yu, X; Zaki, M | 1 |
| Arnulf, B; Attal, M; Avet-Loiseau, H; Banos, A; Benboubker, L; Brechiniac, S; Caillot, D; Decaux, O; Dib, M; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fuzibet, JG; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Lacotte, L; Legros, L; Leleu, X; Macro, M; Marit, G; Mathiot, C; Moreau, P; Onraed, B; Pegourie, B; Petillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Tiab, M; Wetterwald, M | 1 |
| Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A | 1 |
| Ashjian, E; Redic, K | 1 |
| Breider, M; Cooper, D; Couto, S; Das, R; Deng, Y; Dhodapkar, KM; Dhodapkar, MV; Hansel, D; Kocoglu, M; Koduru, S; Ren, Y; Sehgal, K; Seropian, S; Thakurta, A; Vasquez, J; Verma, R; Wang, M; Yao, X; Zhang, L | 1 |
| Sun, JJ; Yang, HL; Zhang, C; Zhou, J | 1 |
| Moreau, P; Touzeau, C | 2 |
| Amatya, R; Belch, A; Dimopoulos, M; Gibson, CJ; Jacques, C; Moreau, P; Palumbo, A; San Miguel, J; Schey, S; Song, KW; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Dimopoulos, MA; Palumbo, A; San-Miguel, J; Siegel, D; Sonneveld, P | 1 |
| Chou, T; Doerr, T; Iida, S; Iwasaki, H; Kurihara, M; Matsue, K; Midorikawa, S; Ogawa, Y; Sunami, K; Tobinai, K; Zaki, M | 1 |
| Arnulf, B; Attal, M; Avet-Loiseau, H; Banos, A; Benbouker, L; Brechiniac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fouquet, G; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Moreau, P; Pegourie, B; Petillon, MO; Richez, V; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Wetterwald, M | 1 |
| Fan, L; Hu, C; Ma, X; Ran, X; Yu, H; Zou, Y | 1 |
| Ancora, F; Calafiore, V; Consoli, ML; Conticello, C; Di Raimondo, F; La Fauci, A; Parisi, M; Romano, A | 1 |
| Abouzaid, S; Chen, CC; Hussein, M; McGuiness, CB; Parikh, K; Purnomo, L; Wade, RL | 1 |
| Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Kyle, RA; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V; Russell, SJ; Stewart, AK | 1 |
12 review(s) available for pomalidomide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Sequencing multiple myeloma therapies with and after antibody therapies.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2020 |
An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2021 |
Relapsed and refractory multiple myeloma: new therapeutic strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Remission Induction; Thalidomide; Treatment Outcome | 2014 |
Pomalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide | 2014 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide | 2014 |
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide | 2015 |
Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Multiple Myeloma; Neoplasm Recurrence, Local; Pharmacists; Professional Role; Proteasome Inhibitors; Thalidomide; Treatment Outcome | 2016 |
Multiple myeloma: from front-line to relapsed therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Humans; Methotrexate; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Randomized Controlled Trials as Topic; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Vincristine | 2015 |
Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Risk Factors; Thalidomide | 2015 |
Pomalidomide in the management of relapsed multiple myeloma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2016 |
Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Management; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Prospective Studies; Salvage Therapy; Thalidomide | 2017 |
34 trial(s) available for pomalidomide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2021 |
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide | 2022 |
Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide; Treatment Outcome | 2022 |
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Plasma Cell; Quality of Life; Thalidomide | 2022 |
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2022 |
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Plasma Cell; Thalidomide | 2023 |
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local | 2023 |
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Thalidomide | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Dexamethasone; Europe; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; North America; Progression-Free Survival; Thalidomide; Treatment Outcome | 2019 |
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2020 |
Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide; Treatment Outcome | 2020 |
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2020 |
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Renal Insufficiency; Salvage Therapy; Survival Rate; Thalidomide | 2021 |
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Kinesins; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Orosomucoid; Spain; Thalidomide; Thiadiazoles; Treatment Outcome | 2021 |
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2021 |
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Thalidomide | 2021 |
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Routes; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Patient Safety; Salvage Therapy; Thalidomide; Treatment Outcome | 2021 |
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Progression-Free Survival; Proportional Hazards Models; Thalidomide | 2021 |
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Frail Elderly; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2021 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence; Thalidomide; Treatment Outcome | 2017 |
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2018 |
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dexamethasone; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Retinal Neoplasms; Thalidomide; Treatment Outcome | 2018 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Analysis; Thalidomide; Treatment Outcome | 2019 |
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2019 |
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome | 2019 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2013 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Dexamethasone; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Thalidomide | 2015 |
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 4; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Deletion; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Thalidomide; Translocation, Genetic | 2015 |
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
Topics: Angiogenesis Inhibitors; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Killer Cells, Natural; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; T-Lymphocytes; Thalidomide; Tumor Microenvironment | 2015 |
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Quality of Life; Thalidomide | 2015 |
Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents; Asian People; Dexamethasone; Disease-Free Survival; Female; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy; Thalidomide | 2015 |
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2009 |
36 other study(ies) available for pomalidomide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Thalidomide | 2021 |
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2022 |
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide | 2022 |
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Japan; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2022 |
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2022 |
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pandemics; Retrospective Studies; Thalidomide; United Kingdom | 2022 |
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Standard of Care; Thalidomide | 2022 |
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Frailty; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; United Kingdom | 2023 |
[The efficacy and safety analysis of pomalidomide in the treatment of relapsed/refractory multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2023 |
[Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local | 2023 |
Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2020 |
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Quality of Life; Thalidomide | 2020 |
Pomalidomide-associated progressive multifocal leukoencephalopathy in multiple myeloma: cortical susceptibility-weighted imaging hypointense findings prior to clinical deterioration.
Topics: Aged; Clinical Deterioration; Dexamethasone; Female; Humans; Immunologic Factors; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Multiple Myeloma; Neoplasm Recurrence, Local; Parietal Lobe; Thalidomide; White Matter | 2020 |
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2021 |
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Leukopenia; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pneumonia; Progression-Free Survival; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Thrombocytopenia; Treatment Outcome | 2020 |
A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Treatment Outcome | 2019 |
A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Treatment Outcome | 2019 |
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Proliferation; Dexamethasone; Female; Humans; Immunomodulation; Immunophenotyping; Killer Cells, Natural; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; T-Lymphocytes, Regulatory; Thalidomide | 2020 |
Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Body Weight; Case-Control Studies; Clinical Trials as Topic; Dexamethasone; Drug Interactions; Female; Histocompatibility Antigens Class I; Humans; Male; Multiple Myeloma; Myeloma Proteins; Neoplasm Recurrence, Local; Pharmaceutical Preparations; Receptors, Fc; Recurrence; Thalidomide; Time Factors | 2020 |
Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Minimal Clinically Important Difference; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide; Transplantation, Autologous | 2021 |
Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide.
Topics: Adolescent; Antineoplastic Agents, Immunological; Brain Neoplasms; Child; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Male; Neoplasm Recurrence, Local; Thalidomide; Young Adult | 2021 |
Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Killer Cells, Natural; Lenalidomide; Mesenchymal Stem Cells; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2021 |
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Progression-Free Survival; Proteasome Inhibitors; Retrospective Studies; Thalidomide; United States | 2021 |
Role of MBD3-SOX2 axis in residual myeloma following pomalidomide.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; SOXB1 Transcription Factors; Thalidomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2022 |
Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Female; Germany; Health Surveys; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Transplantation, Autologous | 2017 |
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Disease Management; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Time Factors | 2017 |
[Successful Treatment with Pomalidomide, Bortezomib, and Dexamethasone in a Patient with Frail Refractory and Relapsed Multiple Myeloma with Extramedullary Disease].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2018 |
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multimodal Imaging; Multiple Myeloma; Neoplasm Recurrence, Local; Plasmacytoma; Soft Tissue Neoplasms; Thalidomide | 2019 |
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide | 2019 |
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Oligopeptides; Research Design; Retreatment; Thalidomide | 2019 |
Pomalidomide in the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
Pooled analysis of pomalidomide for treating patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Meta-Analysis as Topic; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Thalidomide | 2015 |
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2016 |
Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retreatment; Thalidomide | 2017 |
Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Retrospective Studies; Thalidomide | 2017 |